Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 183
Filter
1.
Oncogene ; 36(6): 820-828, 2017 02 09.
Article in English | MEDLINE | ID: mdl-27425591

ABSTRACT

Patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) have better responses to radiotherapy and higher overall survival rates than do patients with HPV-negative HNSCC, but the mechanisms underlying this phenomenon are unknown. p16 is used as a surrogate marker for HPV infection. Our goal was to examine the role of p16 in HPV-related favorable treatment outcomes and to investigate the mechanisms by which p16 may regulate radiosensitivity. HNSCC cells and xenografts (HPV/p16-positive and -negative) were used. p16-overexpressing and small hairpin RNA-knockdown cells were generated, and the effect of p16 on radiosensitivity was determined by clonogenic cell survival and tumor growth delay assays. DNA double-strand breaks (DSBs) were assessed by immunofluorescence analysis of 53BP1 foci; DSB levels were determined by neutral comet assay; western blotting was used to evaluate protein changes; changes in protein half-life were tested with a cycloheximide assay; gene expression was examined by real-time polymerase chain reaction; and data from The Cancer Genome Atlas HNSCC project were analyzed. p16 overexpression led to downregulation of TRIP12, which in turn led to increased RNF168 levels, repressed DNA damage repair (DDR), increased 53BP1 foci and enhanced radioresponsiveness. Inhibition of TRIP12 expression further led to radiosensitization, and overexpression of TRIP12 was associated with poor survival in patients with HPV-positive HNSCC. These findings reveal that p16 participates in radiosensitization through influencing DDR and support the rationale of blocking TRIP12 to improve radiotherapy outcomes.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/virology , Carrier Proteins/metabolism , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Head and Neck Neoplasms/radiotherapy , Head and Neck Neoplasms/virology , Papillomaviridae/physiology , Papillomavirus Infections/radiotherapy , Ubiquitin-Protein Ligases/metabolism , Animals , Biomarkers, Tumor , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Carrier Proteins/genetics , Cell Line, Tumor , Cyclin-Dependent Kinase Inhibitor p16/genetics , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/metabolism , Humans , Mice , Papillomaviridae/genetics , Papillomavirus Infections/metabolism , Radiation Tolerance , Random Allocation , Squamous Cell Carcinoma of Head and Neck , Transfection , Ubiquitin-Protein Ligases/genetics , Xenograft Model Antitumor Assays
6.
Strahlenther Onkol ; 188(11): 1031-7, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23053140

ABSTRACT

BACKGROUND AND PURPOSE: Hypoxia and reoxygenation are important determinants of outcome after radiotherapy. HIF-1α is a key molecule involved in cellular response to hypoxia. HIF-1α expression levels have been shown to change after irradiation. The objective of the present study was to explore the prognostic value of HIF-1α expression during fractionated irradiation. MATERIALS AND METHODS: Six human squamous cell carcinoma models xenografted in nude mice were analysed. Tumours were excised after 3, 5 and 10 fractions. HIF-1α expression was quantified by western blot. For comparative analysis, previously published data on local tumour control data and pimonidazole hypoxic fraction was used. RESULTS: HIF-1α expression in untreated tumours exhibited intertumoural heterogeneity and did not correlate with pimonidazole hypoxic fraction. During fractionated irradiation the majority of tumour models exhibited a decrease in HIF-1α expression, whereas in UT-SCC-5 no change was observed. Neither kinetics nor expression levels during fractionated irradiation correlated with local tumour control. CONCLUSION: Our data do not support the use of HIF-1α determined during treatment as a biomarker to predict outcome after fractionated irradiation.


Subject(s)
Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/radiotherapy , Dose Fractionation, Radiation , Gene Expression/radiation effects , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Otorhinolaryngologic Neoplasms/genetics , Otorhinolaryngologic Neoplasms/radiotherapy , Animals , Biomarkers, Tumor/genetics , Blotting, Western , Carcinoma, Squamous Cell/pathology , Cell Hypoxia/radiation effects , Cell Line, Tumor , Female , Male , Mice , Mice, Nude , Neoplasm Transplantation , Nitroimidazoles/pharmacology , Otorhinolaryngologic Neoplasms/pathology , Prognosis , Radiation-Sensitizing Agents/pharmacology , Statistics as Topic , Transplantation, Heterologous
7.
Int J Gynecol Cancer ; 16(3): 1106-11, 2006.
Article in English | MEDLINE | ID: mdl-16803493

ABSTRACT

We investigated the time course of central disease recurrence (CDR) in 2997 patients treated with radiation for stage I-II squamous cell carcinoma of the cervix. CDR rates were 6.8%, 7.8%, and 9.6%, at 5, 10, and 20 years, respectively. The risk of CDR was independently correlated with tumor size (P < 0.0001) but not with FIGO stage. The hazard rate peaked in the first year of follow-up and then fell steeply; after 3 years, the hazard rate was approximately constant at 0.2-0.4% per year. Although after 3 years the risk of CDR was low, it continued to be slightly greater for patients with tumors > or =5 cm than for those with smaller tumors (P= 0.001). Patients who had CDR < 36 months after treatment were less likely to be candidates for salvage therapy and had a poorer post-recurrence survival rate than those with recurrence > or =36 months after treatment (4.5% versus 42.1%, P < 0.0001). The higher rate of CDR in the first 3 years and the poor survival after early recurrence suggest that most early CDRs are true relapses. The relatively stable annual actuarial risk between 3 and 25 years and the better survival rate after late CDR suggest that most "recurrences" after 3 years are actually new neoplasms.


Subject(s)
Neoplasm Recurrence, Local/epidemiology , Uterine Cervical Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Brachytherapy/methods , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/radiotherapy , Combined Modality Therapy/methods , Female , Humans , Middle Aged , Neoplasm Recurrence, Local/mortality , Retrospective Studies , Risk Factors , Salvage Therapy/methods , Salvage Therapy/statistics & numerical data , Survival Rate , Time Factors , Treatment Outcome , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/mortality
8.
Int J Radiat Oncol Biol Phys ; 58(2): 510-8, 2004 Feb 01.
Article in English | MEDLINE | ID: mdl-14751522

ABSTRACT

PURPOSE: It has been suggested that, reminiscent of the regulated proliferative response of normal squamous epithelium, squamous cell carcinomas that have preserved characteristics of differentiation have a greater repopulation capacity during fractionated irradiation than undifferentiated tumors. The aim of the present study was to investigate repopulation in moderately well-differentiated and keratinizing GL human squamous cell carcinomas in nude mice. METHODS AND MATERIALS: GL human squamous cell carcinomas were transplanted s.c. into the right hind leg of NMRI nu/nu mice. Irradiation was performed with 5.4 Gy fractions under clamp hypoxia or with 2 Gy fractions under ambient conditions. Six, 12, or 18 fractions were given daily, every second day, or every third day. Graded top-up doses were applied under clamp hypoxia to determine the tumor control dose 50% (TCD(50)). A total of 20 TCD(50) assays were performed and analyzed using maximum-likelihood techniques. RESULTS: With an increasing number of daily 5.4 Gy fractions under clamp hypoxia, the top-up TCD(50) values decreased significantly from 50.9 Gy (95% CI: 47, 54) after single doses to 0 Gy after 18 fractions. For the same number of fractions, the top-up TCD(50) increased with increasing overall treatment time. The results are consistent with a constant repopulation rate with a clonogenic doubling time (T(clon)) of 12.7 days (8.6, 16.8). Under ambient blood flow, the top-up TCD(50)s for daily 2 Gy fractions decreased significantly, but were less pronounced than for 5.4 Gy fractions under clamp hypoxia. For a given number of fractions under ambient conditions, the top-up TCD(50)s did not increase significantly with overall treatment time, except for irradiation with 12 fractions in 36 days compared to 12 and 24 days. The T(clon) value from these data was 24.0 days (11.6, 36.4). CONCLUSION: Our data demonstrate a slow but significant rate of repopulation of clonogenic tumor cells during fractionated irradiation of GL human squamous cell carcinomas under clamp hypoxia without indication of a change of the repopulation rate during treatment. Less pronounced repopulation was observed for irradiation under ambient conditions, which might be explained by preferential survival of hypoxic and therefore nonproliferating cells. Taken together with our previous studies on poorly differentiated FaDu tumors (Petersen et al., IJROBP 2001;51:483-493), the results support important heterogeneity of kinetics and mechanisms of repopulation, in particular of the influence of the oxygenation status of surviving clonogenic cells on the repopulation rate during fractionated irradiation, in different experimental squamous cell carcinoma.


Subject(s)
Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/radiotherapy , Cell Division , Algorithms , Animals , Cell Hypoxia , Dose-Response Relationship, Radiation , Female , Humans , Lethal Dose 50 , Male , Mice , Mice, Nude , Radiation Tolerance , Time Factors , Transplantation, Heterologous
9.
Int J Radiat Biol ; 80(10): 719-27, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15799617

ABSTRACT

PURPOSE: To investigate the magnitude and kinetics of repopulation in a moderately well differentiated UT-SCC-14 human squamous cell carcinoma [hSCC] in nude mice. This question is of interest because clinical data indicate a higher repopulation capacity in those SCC that have preserved characteristics of differentiation, which appears to be in contrast to results on FaDu and GL hSCC previously reported from this laboratory. METHODS AND MATERIALS: UT-SCC-14 tumours were transplanted subcutaneously into the right hind leg of NMRI nu/nu mice. Fractionated radiation treatments were delivered, either under clamped hypoxia at 5.4 Gy/fraction or under ambient conditions (consistent with an OER of 2.7). Tumours were irradiated every day, every 2nd day, or every 3rd day with 6, 12 or 18 fractions. 1, 2 or 3 days after the last fraction, graded top-up-doses under clamped conditions were given for the purpose of estimating the 50% tumour control dose (TCD50). A total of 22 TCD50 assays were performed and analysed using maximum likelihood techniques. RESULTS: The data demonstrate a slow but significant repopulation of clonogenic cells during fractionated irradiation of UT-SCC-14 hSCC. The results under hypoxic conditions are consistent with a constant repopulation rate, with a clonogenic doubling time (Tclon) of 15.6 days (95% CI: 9.7, 21.4). This contrasts with ambient conditions where Tclon was 68.5 days (95% CI: 124, 161). Both Tclon values are longer than the 6-day volume doubling time of untreated tumours. CONCLUSIONS: Less pronounced repopulation for irradiation under ambient compared to clamped hypoxic conditions might be explained by preferential survival of hypoxic and therefore non-proliferating clonogenic cells. Taken together with previous studies on poorly differentiated FaDu and moderately well differentiated GL hSCC, the results are consistent with considerable variability in the magnitude and kinetics of repopulation in different experimental squamous cell carcinomas, and with a relationship between reoxygenation and repopulation during fractionated irradiation. The differentiation status of hSCC growing in nude mice does not to appear to correlate with the proliferative capacity of clonogenic tumour cells during treatment. The results do not support the hypothesis gained from clinical data of higher repopulation in well-differentiated tumours.


Subject(s)
Cell Division/radiation effects , Dose Fractionation, Radiation , Animals , Carcinoma, Squamous Cell , Cell Hypoxia/radiation effects , Disease Models, Animal , Dose-Response Relationship, Radiation , Humans , Kinetics , Mice , Mice, Nude , Neoplasm Transplantation , Radiation Tolerance , Transplantation, Heterologous , Tumor Cells, Cultured , Tumor Stem Cell Assay
10.
Int J Radiat Biol ; 79(7): 479-86, 2003 Jul.
Article in English | MEDLINE | ID: mdl-14530155

ABSTRACT

PURPOSE: To determine the impact of increased necrotic cell loss on the repopulation rate of clonogenic cells during fractionated irradiation in human FaDu squamous cell carcinoma in nude mice. MATERIALS AND METHODS: FaDu tumours were transplanted into pre-irradiated subcutaneous tissues. This manoeuvre has previously been shown to result in a clear-cut tumour bed effect, i.e. tumours grow at a slower rate compared with control tumours. This tumour bed effect was caused by an increased necrotic cell loss with a constant cell production rate. After increasing numbers of 3-Gy fractions (time intervals 24 or 48 h), graded top-up doses were given to determine the dose required to control 50% of the tumours (TCD50). All irradiations were given under clamp hypoxia. RESULTS: With increasing numbers of daily fractions, the top-up TCD50 decreased from 37.9 Gy (95% CI: 31; 45) after single dose irradiation to 14.1 Gy (8; 20) after irradiation with 15 fractions in 15 days. Irradiation with 18 daily 3-Gy fractions controlled more than 50% of the tumours without a top-up dose. After irradiation with six fractions every second day, the top-up TCD50 decreased to 26.9 Gy (22; 32). No further decrease of the TCD50 was observed after 12 and 18 irradiations every second day. Assuming a constant increase of TCD50 with time, the calculated doubling time of the clonogenic tumour cells (Tclon) was 7.8 days (4.4; 11.3). The Tclon calculated for FaDu tumours growing in pre-irradiated tissues was significantly longer (p=0.0004) than the Tclon of 5.1 days (3.7; 6.5) determined under the same assumptions in a previous study for FaDu tumours growing in normal subcutaneous tissues. CONCLUSIONS: Increased necrotic cell loss by pre-irradiation of the tumour bed resulted in longer clonogen doubling times during fractionated radiotherapy of human FaDu squamous cell carcinoma. This implies that a decreased necrotic cell loss might be the link between reoxygenation and repopulation demonstrated previously in the same tumour model.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Dose Fractionation, Radiation , Animals , Carcinoma, Squamous Cell/pathology , Cell Division/radiation effects , Female , Humans , Male , Mice , Mice, Nude , Necrosis , Neoplasm Transplantation , Neoplastic Stem Cells/radiation effects , Transplantation, Heterologous
11.
Int J Radiat Biol ; 79(7): 503-9, 2003 Jul.
Article in English | MEDLINE | ID: mdl-14530158

ABSTRACT

Dual interpretations are different radiobiological mechanisms that explain theoretically the same observed results. Radiobiological interpretations of the time factor are most frequently based on changes in total dose that produce a given effect. If this dose is increased by different mechanisms (e.g. increasing overall time and decreasing dose per fraction) at the same time, proposals for altered fractionation schemes based on the choice of one or the other mechanism, in principle, can lead to erroneous predictions of outcome. This is especially the case when the analyses are based on retrospective clinical data, where the influence of patient selection is unknown. Examples of dual interpretations taken from the literature on head and neck, melanoma and prostate cancer are discussed.


Subject(s)
Dose Fractionation, Radiation , Neoplasms/radiotherapy , Brachytherapy , Cell Division/radiation effects , Humans , Male , Melanoma/pathology , Melanoma/radiotherapy , Neoplasms/pathology , Prostatic Neoplasms/pathology , Prostatic Neoplasms/radiotherapy , Retrospective Studies , Time Factors , Tonsillar Neoplasms/pathology , Tonsillar Neoplasms/radiotherapy
12.
Semin Radiat Oncol ; 12(1 Suppl 1): 46-9, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11917284

ABSTRACT

A prospective randomized study was conducted to determine whether amifostine (Ethyol) reduces the rate of severe esophagitis and hematologic and pulmonary toxicity associated with chemoradiation or improves control of non-small cell lung cancer (NSCLC). Sixty patients with inoperable stage II or III NSCLC were treated with concurrent chemoradiotherapy. Both groups received thoracic radiation therapy (TRT) with 1.2 Gy/fraction, 2 fraction per day, 5 days per week for a total dose 69.6 Gy. All patients received oral etoposide (VP-16), 50 mg Bid, 30 minutes before TRT beginning day 1 for 10 days, repeated on day 29, and cisplatin 50 mg/m(2) intravenously on days 1, 8, 29, and 36. Patients in the study group received amifostine, 500 mg intravenously, twice weekly before chemoradiation (arm 1); patients in the control group received chemoradiation without amifostine (arm 2). Patient and tumor characteristics were distributed equally in both groups. Of the 60 patients enrolled, 53 were evaluable (27 in arm 1, 26 in arm 2) with a median follow-up of 6 months. Median survival times were 26 months for arm 1 and 15 months for arm 2, not statistically significantly different. Morphine intake to reduce severe esophagitis was significantly lower in arm 1 (2 of 27, 7.4%) than arm 2 (8 of 26, 31%; P =.03). Acute pneumonitis was significantly lower in arm 1 (1 of 27, 3.7%) than in arm 2 (6 of 26, 23%; P =.037). Hypotension (20 mm Hg decrease from baseline blood pressure) was significantly more frequent in arm 1 (19 of 27, 70%) than arm 2 (1 of 26, 3.8%; P =.0001). Only 1 patient discontinued treatment because of hypotension. These preliminary results showed that amifostine significantly reduced acute severe esophagitis and pneumonitis. Further observation is required to assess long-term efficacy.


Subject(s)
Amifostine/therapeutic use , Antineoplastic Agents, Phytogenic/therapeutic use , Carcinoma, Non-Small-Cell Lung/radiotherapy , Etoposide/therapeutic use , Lung Neoplasms/radiotherapy , Radiation Injuries/prevention & control , Radiation-Protective Agents/therapeutic use , Adult , Aged , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/mortality , Combined Modality Therapy , Esophagitis/etiology , Esophagitis/prevention & control , Female , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/mortality , Male , Middle Aged , Radiation Pneumonitis/prevention & control
13.
Cancer ; 92(8): 2220-7, 2001 Oct 15.
Article in English | MEDLINE | ID: mdl-11596041

ABSTRACT

BACKGROUND: Several methods are used to estimate risks of local and distant failure after treatment of breast carcinoma. The authors' purpose was to present a physician-friendly description of the potential bias in these methods, and to suggest an improvement. METHODS: The cumulative incidence based on first event (cumulative incidence [CI]) and Kaplan-Meier method based on first (KM[1st]) or all (KM[any]) events, are applied to a database comprising 2521 women treated for breast carcinoma at the same institution and observed for more than 20 years. The authors relate these estimates to the region containing all possible estimates of failure rate. This region contains the "true" risk (net risk, or risk that would be observed in the absence of competing risks) of local or distant failure. RESULTS: The CI estimate is the lowest possible estimate of the true failure rate. Under certain "commonsense" assumptions, the CI estimate is below the lowest possible estimate of risk of failure. The KM(1st) estimate is higher than the CI estimate and lower than the KM(any) estimate. Under the same commonsense assumptions, the KM(1st) method also underestimates the true failure rate. CONCLUSIONS: Methods based on time to first event such as CI and KM(1st) underestimate the true risk. In the design of clinical trials, consideration should be given to longer follow-up and the KM(any) method of analyzing results because it provides a less biased estimate.


Subject(s)
Breast Neoplasms/therapy , Survival Analysis , Treatment Failure , Bias , Breast Neoplasms/mortality , Female , Humans , Middle Aged , Prognosis , Risk Factors
14.
Int J Radiat Oncol Biol Phys ; 51(2): 483-93, 2001 Oct 01.
Article in English | MEDLINE | ID: mdl-11567825

ABSTRACT

PURPOSE: FaDu human squamous cell carcinoma (FaDu-hSCC) showed a clear-cut time factor during fractionated radiotherapy (RT) under ambient blood flow. It remained unclear whether this is caused solely by proliferation or if radioresistance resulting from increasing hypoxia contributed to this phenomenon. To address this question, repopulation of clonogenic FaDu cells during fractionated RT under clamp hypoxia was determined by local tumor control assays, and compared to the results after irradiation with the same regimen under ambient blood flow. METHODS AND MATERIALS: FaDu-hSCC was transplanted into the right hind leg of NMRI nu/nu mice. In the first set of experiments, irradiation was performed under clamp hypoxia. After increasing numbers of 3 Gy fractions (time intervals 24 h or 48 h), graded top-up doses were given to determine the TCD(50) (dose required to control 50% of the tumors). In the second set of experiments, all 3 Gy fractions were applied under ambient conditions, but as in the previous experiments the graded top-up doses were given under clamp hypoxia. A total of 26 TCD(50) assays were performed and analyzed using maximum likelihood techniques. RESULTS: With increasing numbers of daily fractions, the top-up TCD(50) under clamp hypoxia decreased from 39.4 Gy [95% CI 36, 42] after single dose to 19.8 Gy [15, 24] after 18 fractions in 18 days and to 37.8 Gy [31, 44] after 18 fractions in 36 days. The results were consistent with biphasic repopulation, with a switch to rapid repopulation after about 22 days [13, 30]. The clonogen doubling time (T(clon)) decreased from 9.8 days [0, 21] in the beginning of RT to 3.4 days after 22 days. Under ambient blood flow the top-up TCD(50) decreased from 37.6 Gy [34, 40] after single dose irradiation to 0 Gy [0, 1] after 18 fractions in 18 days and 22.4 Gy [18, 27] after 18 fractions in 36 days. Similar to results from irradiations under clamp hypoxia, the ambient data were consistent with a biphasic course of clonogen inactivation. Comparison of both data sets revealed significant reoxygenation after 12 fractions. CONCLUSIONS: Our data are most consistent with a biphasic course of clonogen repopulation during fractionated RT of FaDu-hSCC under clamp hypoxia with a switch in T(clon) after about 22 days of treatment ("dog-leg"). A similar biphasic course of cell repopulation was observed under ambient conditions. The temporal coincidence between repopulation and reoxygenation suggests that the latter might be the stimulus for proliferation in FaDu tumors.


Subject(s)
Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/radiotherapy , Animals , Carcinoma, Squamous Cell/physiopathology , Cell Division , Cell Hypoxia/physiology , Dose Fractionation, Radiation , Dose-Response Relationship, Radiation , Humans , Likelihood Functions , Mice , Mice, Nude , Neoplasm Transplantation , Radiation Tolerance , Radiobiology , Temperature , Time Factors , Tumor Cells, Cultured/radiation effects
16.
Radiat Res ; 155(6): 866-9, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11352770

ABSTRACT

Several lines of correlative evidence link transforming growth factor alpha (Tgfa, also known as TGF-alpha) to proliferative activity in jejunal crypt cells. It is therefore tempting to hypothesize that, as a ligand of the epidermal growth factor, it mediates the compensatory proliferative burst in the crypts after radiation-induced cell killing. We have tested this hypothesis by comparing the repopulation response of wild-type and Tgfa-null mice, using the microcolony assay. Mice were exposed whole-body to (137)Cs gamma rays at a dose of approximately 1.6 Gy/min. Single doses and equal doses separated by 4 and 54 h were given. The rightward shift of the dose-response curves for 54 h was identical for wild-type and Tgfa-null mice, and there was no indication of a difference in radiosensitivity. This result indicates that Tgfa is not an essential component of the proliferative response of tissue to radiation-induced cell killing.


Subject(s)
Cell Division/radiation effects , Jejunum/radiation effects , Transforming Growth Factor alpha/physiology , Animals , Dose-Response Relationship, Radiation , Jejunum/cytology , Mice , Mice, Inbred C57BL , Mice, Knockout , Transforming Growth Factor alpha/genetics
17.
Int J Radiat Oncol Biol Phys ; 50(2): 397-403, 2001 Jun 01.
Article in English | MEDLINE | ID: mdl-11380226

ABSTRACT

PURPOSE: Postmastectomy irradiation improves overall survival for breast cancer patients at high risk for locoregional recurrence (LRR). The objective of this study was to use recursive partitioning analysis (RPA) to define patient subgroups at high risk for LRR following mastectomy. PATIENTS AND METHODS: A cohort of 1031 patients treated on prospective trials with mastectomy and doxorubicin-based chemotherapy without irradiation was analyzed. The variables considered in the RPA were tumor size, number of involved nodes, number of nodes examined, and percentage of nodes involved (nodes involved/nodes examined). The endpoint was LRR +/- distant metastasis. Only patients with complete data were analyzed (n = 913). Median follow-up was 8 years (range, 0.7-22 years). RESULTS: Involvement of 20% or more of the lymph nodes examined was the most significant variable predicting LRR. Three risk categories were defined. Patients with 20% or more involved nodes and tumors of 3.5 cm or more were at greatest risk for LRR (41% at 8 years). An intermediate-risk group included patients with 20% or more involved nodes and tumors of less than 3.5 cm as well as those with less than 20% involved nodes and tumor size of 5 cm or greater (18% at 8 years). Patients with less than 20% involved nodes and tumor size of less than 5 cm were at lowest risk for LRR (10% at 8 years). CONCLUSION: Tumor size and extent of nodal involvement play interrelated roles in predicting LRR following mastectomy and systemic therapy. Patients with 20% or greater involved nodes and those with less than 20% nodes and tumors of 5.0 cm or greater are at significant risk of LRR and should be considered for postoperative irradiation.


Subject(s)
Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Neoplasm Recurrence, Local , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Cohort Studies , Doxorubicin/administration & dosage , Female , Humans , Mastectomy, Modified Radical , Middle Aged , Neoplasm Staging , Prognosis , Radiotherapy, Adjuvant , Survival Analysis
18.
Dis Colon Rectum ; 44(3): 322-33; discussion 333-4, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11289276

ABSTRACT

PURPOSE: Both negative and positive influences of mutant p53 on treatment outcome have been reported, and we present here a meta-analysis of published studies where outcome was reported for defined treatment groups. METHODS: We identified articles on the effect of p53 status by treatment modality, excluding those not stratified by method of treatment. A common hazard ratio was estimated from studies that reported a multivariate analysis. We also estimated the numbers of patients expressing the endpoint at the mean or median follow-up time and calculated a pooled odds ratio. RESULTS: Twenty-eight articles were evaluable (23 using immunohistochemistry to detect overexpression of p53 and 8 using DNA sequencing), for a total of 4,416 patients. For patients treated with surgery only, the immunohistochemistry studies showed a significant influence of p53 status on disease-free survival and a marginally significant influence on overall survival. In the studies using DNA sequencing, by contrast, there was a significant influence of p53 mutations on overall survival, but not disease-free survival. For patients treated with surgery and radiotherapy, the influence of p53 status on disease-free survival was either insignificant or marginally significant, depending on test used; there was no influence on overall survival. CONCLUSIONS: Although this pooled analysis of published studies where treatment was accounted for shows that there is a borderline significant hazard associated with p53 overexpression or mutation vs. p53 wild-type, it is unlikely that p53 can be applied in a routine clinical setting alongside factors such as T stage, nodal status, and residual tumor, whose prognostic value is much stronger.


Subject(s)
Adenocarcinoma/genetics , Colorectal Neoplasms/genetics , Tumor Suppressor Protein p53/genetics , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Colorectal Neoplasms/surgery , Follow-Up Studies , Humans , Neoplasm Staging , Prognosis , Survival Rate
19.
Ann Hematol ; 80(1): 2-8, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11233771

ABSTRACT

The results of individual studies examining the role of p53 as a predictive and prognostic factor in lymphoid malignancies have varied considerably. In order to summarize the available data on the overexpression or mutation of p53 in Hodgkin's and non-Hodgkin's lymphoma, a systematic literature review was performed. Twenty-four studies met the eligibility criteria. With respect to non-Hodgkin's lymphoma, most studies seem to support the hypothesis that patients whose tumors contain wild-type p53 respond better to treatment and have increased survival rates. If true, the implication may be that patients with p53 mutated tumors could be selected for non-standard treatment. With respect to Hodgkin's lymphoma, comparable associations were rarely reported. However, techniques for assessing the inactivation of p53 varied widely. Furthermore, in most instances, the study design and/or statistical methods did not allow sufficient analyses of the influence of confounding factors such as histologic type, stage, first-line and salvage treatment, etc. Therefore, it remains unclear whether the apparent influence of p53 status on outcome in non-Hodgkin's lymphoma is independent of established parameters such as stage, performance status, etc. Further studies involving large numbers of specimens derived from patients treated in clinical trials with identical regimens, follow-up and salvage strategies are needed. These studies should also be stratified according to histologic subtypes.


Subject(s)
Genes, p53 , Hodgkin Disease/genetics , Lymphoma, Non-Hodgkin/genetics , Disease-Free Survival , Genes, p53/genetics , Hodgkin Disease/mortality , Humans , Lymphoma, B-Cell/genetics , Lymphoma, Non-Hodgkin/mortality , Mutation , Prognosis , Survival Rate
20.
Int J Radiat Oncol Biol Phys ; 49(2): 345-51, 2001 Feb 01.
Article in English | MEDLINE | ID: mdl-11173127

ABSTRACT

PURPOSE: To address whether the translational research chain has influenced clinical practice in radiation oncology. METHODS AND MATERIALS: Merits and limitations of the various steps of the translational chain, i.e., in vitro studies, animal experiments, biomathematical modeling, Phase I and II trials, and randomized Phase III trials are briefly reviewed. The process and value of translational research in radiation oncology are addressed using dose fractionation and the time factor in tumors as examples. RESULTS: The examples show that translational research may indeed change clinical practice in radiation oncology. However, it takes several decades and considerable efforts to define and test new strategies. The "translational process" is by no means unidirectional but a continuing multiway dialog among basic scientists, applied scientists, clinical scientists, and clinical oncologists. CONCLUSION: Translational research works in radiation oncology, and it is difficult to conceive a better alternative for future improvement of therapy. The slow speed of the translational process indicates that there is a need for improving the various steps of the translational network and the interaction as a whole. Massive investments in one part of the network are likely to be at least partly wasted unless the other links are strengthened as well.


Subject(s)
Diffusion of Innovation , Neoplasms/therapy , Radiation Oncology/methods , Animals , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Dose Fractionation, Radiation , Humans , Mice , Models, Animal , Models, Biological , Randomized Controlled Trials as Topic , Research , Time Factors , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...